Actively Recruiting
Dapagliflozin in Depression
Led by Tanta University · Updated on 2025-11-25
60
Participants Needed
1
Research Sites
59 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Major depressive disorder (MDD) is currently one of the leading causes of disability and suicidal death worldwide, and despite extensive research and massive improvements in mental health, the nature of MDD remains ambiguous. Moreover, about two-thirds of MDD patients fail to optimally respond to currently available standard therapies, and many of them suffer from treatment-resistant depression
CONDITIONS
Official Title
Dapagliflozin in Depression
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Both male and female participants included
- Negative pregnancy test and use of effective contraception for females
- Diagnosed with depression for at least 2 months
- Hamilton Depression Rating Scale score greater than 18
You will not qualify if you...
- Diagnosis of bipolar I or bipolar II disorder, personality disorders, or eating disorders
- Substance dependence or abuse
- History of seizures or receiving electroconvulsive therapy (ECT)
- Presence of inflammatory disorders
- Allergy or contraindication to study medications
- Currently pregnant or breastfeeding
- Diagnosis of diabetes
- Severe kidney disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mostafa Bahaa
Damietta, New Damietta, Egypt, 34518
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here